Retour sur lavenir.net
   FAGRON 23.900 € (+0,42 %)     PROXIMUS 6.630 € (-0,30 %)     AB INBEV 62.120 € (-0,74 %)     RETAIL ESTATES 69.400 € (-0,57 %)     WDP 23.920 € (+0,17 %)     ARGENX SE 678.400 € (-1,17 %)     BIOTALYS 2.230 € (-2,41 %)     KINEPOLIS GROUP 29.950 € (-1,48 %)     FLUXYS BELGIUM D 21.400 € (-0,47 %)     NEXTENSA 46.450 € (-0,04 %)     BQUE NAT. BELGIQUE 398.000 € (-0,25 %)     BANQUP GROUP 2.590 € (-5,47 %)     CARE PROPERTY INV. 12.800 € (-0,16 %)     SYENSQO 55.350 € (-0,63 %)     AEDIFICA 73.700 € (+0,14 %)     CMB.TECH 10.820 € (-3,91 %)     VAN DE VELDE 32.300 € (-0,62 %)     KBC 115.450 € (-1,95 %)     UCB 243.100 € (-1,62 %)     D'IETEREN GROUP 180.000 € (-1,48 %)     TESSENDERLO 21.250 € (+0,71 %)     NYXOAH 2.790 € (-0,36 %)     CFE 11.200 € (-0,88 %)     AZELIS GROUP 10.390 € (+0,29 %)     ENERGYVISION 13.300 € (0,00 %)     EXMAR 10.800 € (+0,47 %)     SIPEF 97.100 € (+2,21 %)     XIOR 27.500 € (-0,54 %)     SEQUANA MEDICAL 0.530 € (+1,53 %)     DECEUNINCK 2.130 € (-2,07 %)     AGFA-GEVAERT 0.482 € (-1,13 %)     UMICORE 17.380 € (-1,25 %)     ORANGE BELGIUM 20.500 € (0,00 %)     ECONOCOM GROUP 1.490 € (+0,34 %)     SHURGARD 27.550 € (-1,08 %)     TITAN S.A. 46.420 € (-0,68 %)     ONTEX GROUP 2.970 € (-2,30 %)     WAREHOUSES ESTATES 42.000 € (+1,20 %)     BPOST 1.884 € (+0,11 %)     HOME INVEST BE. 19.140 € (-0,10 %)     COFINIMMO 86.300 € (+0,06 %)     ACKERMANS V.HAAREN 276.400 € (-1,00 %)     CENERGY 20.680 € (-2,27 %)     BREDERODE 103.400 € (-0,19 %)     AGEAS 68.050 € (-0,80 %)     BIOSENIC 0.002 € (-8,33 %)     BEKAERT 41.650 € (-0,48 %)     SOFINA 223.400 € (-1,15 %)     VIOHALCO 14.300 € (-1,38 %)     VGP 92.300 € (-0,32 %)     VASTNED 30.450 € (+1,16 %)     TUBIZE-FIN 209.000 € (-2,70 %)     SOLVAC NOM(RETAIL) 74.000 € (0,00 %)     LOTUS BAKERIES 10 000.000 € (+0,60 %)     GBL 80.200 € (-0,62 %)     GIMV 48.500 € (-0,31 %)     IBA 14.280 € (-0,83 %)     BARCO 9.335 € (-0,95 %)     ONWARD MEDICAL 3.005 € (+3,44 %)     KBC ANCORA 78.000 € (-1,14 %)  
   STMICROELECTRONICS 37.460 € (-0,40 %)     ESSILORLUXOTTICA 201.500 € (-2,52 %)     GECINA 72.200 € (-0,28 %)     KERING 238.100 € (-2,10 %)     DASSAULT AVIATION 304.800 € (-2,25 %)     CEGEDIM 12.150 € (+0,41 %)     ORANGE 17.360 € (-1,62 %)     ATOS 35.560 € (-1,88 %)     THALES 242.000 € (-2,30 %)     HEINEKEN HOLDING 62.000 € (+0,08 %)     Vusion 123.500 € (+3,96 %)     WORLDLINE 0.308 € (+0,42 %)     ARVERNE GROUP 5.800 € (+1,40 %)     CSG 20.310 € (-3,47 %)     AIRBUS 166.240 € (-2,51 %)     FDJ UNITED 24.310 € (-7,95 %)     BIOMERIEUX 88.750 € (-2,04 %)     2CRSI 41.980 € (+3,09 %)     AHOLD DEL 41.640 € (+0,34 %)     EXPLOSIFS PROD.CHI 275.000 € (+5,77 %)     LOUIS HACHETTE 1.689 € (-2,43 %)     VIRBAC 379.500 € (-1,17 %)     HAVAS 16.300 € (+0,62 %)     AXA 41.440 € (-2,31 %)     SES 6.560 € (+3,23 %)     PLANISWARE 18.620 € (-0,43 %)     DELFINGEN 30.000 € (-1,64 %)     ASML HOLDING 1 249.800 € (+1,03 %)     ADOCIA 4.736 € (-17,20 %)     JCDECAUX 19.140 € (-0,47 %)     SOCIETE GENERALE 70.370 € (-1,94 %)     TF1 6.795 € (-0,51 %)     S.E.B. 48.760 € (-0,49 %)     MERCIALYS 12.640 € (-0,16 %)     CAPGEMINI 106.750 € (-2,51 %)     ING GROEP N.V. 24.150 € (-1,41 %)     VALLOUREC 24.590 € (+3,80 %)     KPN KON 4.626 € (+0,19 %)     ALFEN 11.930 € (+6,33 %)     SCOR SE 32.420 € (-1,58 %)     ARKEMA 61.900 € (+0,49 %)     UMG 20.010 € (-0,35 %)     ALLFUNDS GROUP 8.775 € (+0,29 %)     VIRIDIEN 150.700 € (+5,53 %)     INPOST 15.200 € (-0,33 %)     SARTORIUS STED BIO 184.000 € (-2,39 %)     APERAM 41.380 € (-0,53 %)     AALBERTS NV 31.340 € (-0,32 %)     UNILEVER 48.610 € (-0,20 %)     SAINT GOBAIN 76.920 € (-1,91 %)     RELX 31.580 € (-1,31 %)     NEXANS 135.500 € (-0,15 %)     PUBLICIS GROUPE SA 78.480 € (-0,38 %)     HERMES INTL 1 645.500 € (-1,82 %)     ASR NEDERLAND 63.640 € (-0,59 %)     SHELL PLC 38.010 € (+0,84 %)     FORVIA 10.210 € (-1,26 %)     BE SEMICONDUCTOR 232.300 € (+1,93 %)     DANONE 68.080 € (+2,50 %)     L'OREAL 344.900 € (-0,07 %)  
News Réglementées
22/04/2026 19:59

Inside Information / News release on accounts, results

Samsonweg 2
1521RC Zaanstad
Tel. 075-7572685
info@petserviceholding.com
www.petserviceholding.com

Pet Service Holding Reports 2025 Annual Results and Strengthens Strategic Growth Platform

Revenue growth maintained in transition year, with new growth drivers supporting outlook for accelerated development in 2026

Zaanstad, 22 April 2026 – 7 pm (CEST)

Pet Service Holding NV (Euronext Growth Paris, ISIN: NL0015001HZ9 / Ticker: ALPET), today announces its annual results for the financial year ended 31 December 2025, reflecting a year of strategic transition in which the Company continued to expand its business platform while addressing temporary regulatory challenges affecting part of its veterinary activities.

Ron Van Veldhoven, CEOof Pet Service Holding, commented:

“2025 was an important transition year in which we absorbed short-term pressure while building a stronger and broader platform for future growth. Despite temporary regulatory headwinds, we continued to invest in new commercial opportunities, expanded our portfolio through acquisition, and laid the foundation for scalable growth. We believe these strategic steps position PSH well for accelerated development in 2026 and beyond.”

Simplified Consolidated Profit & Loss

In Euros

20252024
Turnover13 595 74512 728 996
Revenues from E-commerce platform sales8 998 1468 486 735
Revenues from Wholesale, veterinarians and pet shops sales4 386 5224 157 438
Other revenues211 07784 823
Cost of sales-9 152 435-8 154 758
Gross margin4 443 3104 574 238
Operating expenses4 233 9134 114 152
 Employee expenses1 047 676963 973
 Other operating expenses3 186 2373 150 179
Operating margin209 397460 086
Holding expenses544 778399 626
EBITDA-335 38160 460
Depreciation and amortization fixed assets479 152446 409
Financial expenses375 773-23 692
Other non-operational income75 0400
Net result before tax-1 265 346-362 257
Corporate income tax335 763450 557
Net result after tax-929 58388 300

Revenue for 2025 amounted to €13.6 million, representing an increase of 7.0% compared to 2024, supported by continued demand across core product categories and the development of new commercial initiatives.

While profitability remained under temporary pressure during the year, this development reflects deliberate investments in growth, integration capacity, commercial infrastructure and future scalability.

Operating expenses increased from €4.1 million in 2024 to €4.2 million in 2025, in line with the increase in revenues. Beyond employees’ expenses, reflecting the investment in human capital, the main contributors to the operating expenses were the marketing costs and the distribution & delivery costs. Holding expenses increased from €0.40 million to €0.54 million.

EBITDA for the year was -€0.34 million, decreasing from €0.06 million in 2024, in line with management expectations. This performance reflects higher investment in marketing and staff, the expansion of operational infrastructure, costs related to acquisition financing, and temporary external factors affecting certain revenue streams.

Financial performance reflects strategic investments

During 2025, PSH continued to invest in strengthening its long-term operating platform.

Key financial developments included the ongoing expansion of commercial capabilities, reinforcement of organizational capacity, targeted investments to support future revenue diversification, and financing aligned with the Group’s acquisition and growth ambitions.

These investments were made while maintaining revenue growth, despite temporary disruptions affecting one regulated segment within the veterinary division.

Capital structure further strengthened

At year-end, the Company’s cash position amounted to €1.0 million, reflecting continued investment in growth and working capital development during the year.

During 2025 and in the first months of 2026, PSH continued to actively strengthen its financial structure in support of its long-term growth strategy. A key milestone in this process was the agreement to include a mandatory conversion clause at the end of the bond term of 2027 for nearly €1 million of outstanding convertible bonds into equity. This measure is expected to strengthen the Company’s balance sheet and reduce financial leverage.

This development improves the Company’s financial flexibility and creates a more robust foundation for the execution of future strategic initiatives, including acquisitions, retail expansion and further development of new revenue streams.

In addition, PSH is seeking the refinancing of the building in Boxtel acquired in 2024. The initial repayment date is expected by the end of 2026. This refinancing will further improve the financial flexibility of the Company.

As PSH continues to execute its expansion plans, management remains attentive to capital allocation and may evaluate additional financing opportunities over the coming twelve months, depending on the pace of operational development and market conditions.

KEY HIGHLIGHTS OF 2025

Regulatory Developments within Veterinary Activities

During 2025, PSH experienced evolving European regulatory conditions affecting part of its veterinary product portfolio. In close consultation with the Dutch Food and Consumer Product Safety Authority, the Company suspended sales of certain prescription-related veterinary products outside of The Netherlands in the second half of 2025 to ensure full compliance with applicable EU regulations.

This led to an approximate €1 million temporary impact on revenue in Q4 2025, short-term pressure within a specific regulated category, and temporary limitations on certain international veterinary sales activities.

Management considers these effects to be temporary and expects that increased regulatory clarity will support a gradual normalization over time. In parallel, the Company continues to reduce its dependence on regulated product categories by accelerating growth in segments that are less sensitive to regulatory constraints.

Strategic Expansion through Acquisition of Petlux

In H2 2025, PSH acquired a majority stake in Petlux BV, strengthening its position in premium pet products and accessories.

Strategic benefits include:

  • expansion into higher-margin premium categories,
  • broadening of the Group’s product portfolio,
  • access to a European distribution network of more than 250 retail locations.

Expected annual revenue contribution in 2026 amounts to approximately €3 million, with a positive contribution anticipated to future gross margin development.

Initial integration costs will be visible during 2025–2026 as the business is incorporated into the wider Group platform.

New Growth Drivers Continue to Expand

Throughout 2025, PSH further developed several new commercial pillars designed to reduce dependency on historically regulated revenue streams and strengthen long-term growth potential.

This included expansion of OTC product ranges, continued growth in accessories and lifestyle products, further development of direct customer relationships through data-driven marketing, and a strategic cooperation with Figo Pet Insurance.

These initiatives form part of a broader strategy aimed at building a more diversified and scalable business model.

BudgetPets Introduced as a New Retail Growth Platform

A major strategic development during 2025 was the preparation for the launch of BudgetPets, a new retail concept focused on affordable quality pet products with strong turnover characteristics.

The first store is expected to open in Bussum in July 2026, at a location adjacent to a supermarket with estimated daily footfall of 1,800 to 2,000 visitors.

The concept is designed around an efficient operating structure, high product turnover and increasing private label penetration, while benefiting from integration with the Group’s existing logistics and e-commerce infrastructure.

Management views BudgetPets as an important new growth pillar with potential to contribute both to revenue development and structural margin improvement over time.

2026 Outlook

For 2026, PSH anticipates a clear acceleration in growth, supported by several strategic drivers that were developed or initiated during 2025. Management expects the gradual normalization of veterinary activities, combined with the full-year contribution of Petlux BV, to contribute materially to revenue development over the coming year.

At the same time, continued expansion in non-regulated product categories, including accessories, lifestyle products and OTC offerings, is expected to further improve the revenue mix and reduce dependency on historically regulated segments. The first commercial contribution from the BudgetPets retail concept is also expected to support growth during the second half of the year, following the planned opening of the first store in Bussum.

Based on current developments, the Company anticipates revenue growth towards approximately €17–18 million in 2026, accompanied by an improvement in operating margins.

About Pet Service Holding NV

Pet Service Holding NV is a leading player in the pet care sector in the Netherlands. The company distinguishes itself in this competitive market by bringing together a broad range of services and leveraging its valuable experience and expertise in the field. With a focus on pet supplies, nutrition, and products for veterinary practices, Pet Service Holding is well positioned to meet the needs of pets and their owners throughout Europe.

Ticker: ALPET (Euronext Growth Paris) – ISIN: NL0015001HZ9

Also separately listed on Nxchange Amsterdam (ISIN: NL00150004O8) in the form of depositary receipts (DRs) of shares.

Contacts

Pet Service Holding
Ron van Veldhoven
Chief Executive Officer
+31-75-7572685
info@petserviceholding.com

NewCap
Dusan Oresansky
Investor Relations
+33 1 44 71 94 92
petserviceholding@newcap.eu

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière